It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...